Analysis: New Medicare Program Opens Door for Older Americans to Access Weight-Loss Drugs at $50 a Month
By Chris Prentice and Amina Niasse
NEW YORK, July 1 (Reuters) – Millions of older Americans who have long been priced out of the booming market for GLP-1 weight-loss drugs will soon gain access to them at a fraction of the cost, thanks to a new Medicare pilot program launching Wednesday. The initiative, which caps monthly out-of-pocket expenses at $50, is expected to dramatically expand the reach of drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which have become cultural touchstones but remained out of reach for many seniors.
The 18-month trial, overseen by the U.S. Centers for Medicare & Medicaid Services (CMS), marks a significant policy shift. For years, Medicare was barred from covering weight-loss medications alone, only paying for them when prescribed for related conditions such as cardiovascular disease or severe fatty liver disease. The new program allows coverage specifically for obesity, opening three distinct pathways for eligible subscribers to qualify.
A CMS official recently estimated that eligible patients number in the single-digit millions, while Wall Street analysts project the program could generate billions in revenue for drugmakers. The KFF, a health research organization, offered a more conservative estimate of nearly 4 million beneficiaries based on 2023 data.
The price tag – $50 a month versus the typical $1,000 or more – represents a seismic shift for patients who have faced steep out-of-pocket costs, even with private insurance. For many seniors living on fixed incomes, the change is life-altering.
“This is a huge win. For decades, medicine failed to recognize obesity as a disease,” said Dr. Christina Nguyen of Knownwell, a weight-loss clinic in Atlanta. “Even with program restrictions, we can offer medications to many patients for the first time.”
PATIENTS EAGER, BUT CAUTIOUS
Katie Smith, 71, a retired teacher in Manassas, Virginia, said her doctor prescribed a GLP-1 drug, but the cost at her pharmacy was prohibitive. “The quote was $1,298.99. Medicare won't cover it because I'm not diabetic and don't have sleep apnea,” she said, describing common conditions that previously qualified for coverage.
Smith, who uses a walker after a spinal cord injury from a car accident decades ago, said her weight has complicated her mobility. “It's not good to be carrying this extra weight. They say it's diet and exercise – I've tried it all,” she said. “It could be that I won't tolerate a GLP-1, but I would so like to try it.”
Sandi Henderson, 77, of Oxnard, California, had lap-band surgery years ago but needed the band removed due to complications. She now buys compounded GLP-1 drugs because branded versions cost $149 to $399 monthly through patient-assistance programs, or more at retail pharmacies. “I'm thrilled. The ability to have this drug accessible to people who haven't been able to afford it – just wow, it brings tears to my eyes,” she said in a phone interview. “And we'll save $1,000-plus that we can invest in other parts of our health.”
PENT-UP DEMAND AND IMPLEMENTATION HURDLES
Industry executives have pointed to estimates of up to 20 million people potentially qualifying, though the more conservative KFF figure suggests the actual number may be lower. Dr. Jorge Moreno, an obesity specialist at Yale Medicine, said he has already seen patients rescheduling appointments to July specifically to take advantage of the program. “There's a lot of excitement from patients. I've been getting messages almost daily,” he said.
Yet the rollout is expected to face friction. Two pharmacy trade organizations warned that the mid-year launch leaves little time for pharmacists to learn program details, and prior authorization requirements from clinicians could cause delays. Knownwell's Nguyen said her practice has hired additional staff and is preparing patients for pre-authorization that could take “a couple of weeks or more.”
Pharmacies are also expected to keep limited inventories of the expensive GLP-1 drugs, potentially leading to longer wait times for patients.
BIG BENEFITS, REAL RISKS FOR SENIORS
Dr. John Batsis, a geriatric specialist at the University of North Carolina, urged a measured approach. “This is an important development for access, but older adults should treat GLP-1 therapy as part of a comprehensive obesity-care plan, not as a standalone medication,” he said. “For older adults, the main concern is not simply pounds lost, but what type of weight is lost.”
As GLP-1 use has surged, concerns about muscle mass loss have grown – particularly for seniors who may already be at risk of sarcopenia. If weight is regained, experts worry it may return as fat rather than muscle, worsening metabolic health.
Dr. Elbert Huang, a primary care physician and director of the Center for Chronic Disease Research and Policy at the University of Chicago, highlighted the temporary nature of the program as a key risk. The pilot runs through 2027, leaving uncertainty for patients who start the drugs. “To me, the big scientific uncertainty is how long one needs to stay on the drugs to reap the benefits of weight loss,” Huang said. “If you're someone signing up for this program, which is only in place temporarily, what happens after 2027?”
If the pilot succeeds, it could pave the way for broader coverage by private insurers, many of which have expressed reservations about the cost. For now, the program offers a glimpse of a future where weight-loss medications are no longer a luxury only the wealthy can afford.
(Reporting by Chris Prentice and Amina Niasse in New York; Additional reporting by Mariam Sunny in Bengaluru; Editing by Caroline Humer and Bill Berkrot)